Furthermore, Rh2 did not induce splenomegaly, one of the characteristics of systemic immune dysfunction, suggesting that treatment with Rh2 is safe and subsequently that it could be an efficient agent for the treatment of AD. Here, RHAG is linked to Splenomegaly.